SCHEMBL442875

SCHEMBL442875

[c]1cccc(SCc2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.49
MAOB P27338 3/20 0.49
POLB P06746 3/20 0.41
HSD17B10 Q99714 1/20 0.41
SLC6A4 P31645 1/20 0.41
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
DAO P14920 1/20 0.38
PPARG P37231 2/20 0.38
PPARA Q07869 2/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6664933 0.80 APP (0.54) MAOAMAOBMEN1KMT2ADAO
SCHEMBL332623 0.79 MAOA (0.63) MAOAMAOBPOLBHSD17B10SLC6A4
SCHEMBL402875 0.78 MAOA (0.58) MAOAMAOBPOLBHSD17B10SLC6A4
SCHEMBL1712262 0.78 MAOA (0.53) MAOAMAOBPOLBHSD17B10SLC6A4
SCHEMBL28084553 0.77 MAOA (0.61) MAOAMAOBPOLBHSD17B10SLC6A4
SCHEMBL6662388 0.76 CA12 (0.41) KMT2ANPC1RAB9ASMN1; SMN2HTT
SCHEMBL21981583 0.74 BRD4 (0.32) HSD17B10NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL10055053 0.74 ALDH1A1 (0.57) MAOAMAOBPOLBHSD17B10SLC6A4
SCHEMBL3612916 0.74
SCHEMBL972188 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024112258-A1 SEROTONIN RECEPTOR AS A TARGET FOR THERAPY AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2024-05-30 WO claimed
CN-116323558-A Compounds and methods for treating diseases 艾特里提治疗有限公司 2023-06-23 CN claimed
US-11603364-B2 Acyl hydrazone derivative compounds for treating disease Alterity Therapeutics Limited (AU) 2023-03-14 US claimed
CN-114920753-A 6-fluoro-dihydropyrano [2,3-c ] pyrazole derivative and synthetic method and application thereof 华南理工大学 2022-08-19 CN claimed
US-20220169676-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES WASHINGTON UNIVERSITY (US) 2022-06-02 US claimed
EP-3989997-A1 COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS Washington University (US) 2022-05-04 EP claimed
US-20220073461-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES WARSZAWSKI UNIWERSYTET MEDYCZNY (PL) 2022-03-10 US claimed
EP-3908580-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES UNIWERSYTET JAGIELLONSKI (PL) 2021-11-17 EP claimed
WO-2020264187-A1 COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS JANETKA JAMES (US) 2020-12-30 WO claimed
WO-2020145831-A1 (2,5-DIOXOPYRROLIDIN-L-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES Uniwersytet Jagielloński (PL) 2020-07-16 WO claimed
EP-0593559-A1 AROMATIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY MERCK SHARP & DOHME LTD. (GB) 1994-04-27 EP claimed
EP-0587377-A2 Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1994-03-16 EP claimed
WO-1994001402-A1 HETEROCYCLIC AMIDE DERIVATIVES AS TACHYKININ DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1994-01-20 WO claimed
WO-1993001169-A2 AROMATIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY MERCK SHARP & DOHME LIMITED (GB) 1993-01-21 WO claimed
US-4891383-A Derivatives of 5-pentylamino-5-oxopentanoic and 4-pentylamino-4-oxobutanoic acids with antagonistic activity towards cholecystokinin and a method for their preparation ROTTA RESEARCH LABORARORIUM S.P.A. (IT) 1990-01-02 US claimed
EP-0126311-B1 BENZOPYRAN DERIVATIVES. BEECHAM GROUP PLC (GB) 1989-09-13 EP claimed
US-4616002-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1986-10-07 US claimed
US-4571406-A Anti-hypertensive chromans and chromenes BEECHAM GROUP P.L.C. (GB) 1986-02-18 US claimed
EP-0145956-A1 Composés amidés CIBA-GEIGY AG (CH) 1985-06-26 EP claimed
EP-0126311-A2 Benzopyran derivatives. BEECHAM GROUP PLC (GB) 1984-11-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603364-B2 Acyl hydrazone derivative compounds for treating disease FH, ACOX1, HDAC1 MAOA 532/4885MAOB 564/4885POLB 2517/4885
US-20220073461-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES TRPV5, P2RX5, TRPV1 MAOA 301/4885MAOB 519/4885POLB 3803/4885
US-20220169676-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES HDGF, MMP7, HGF MAOA 362/4885MAOB 747/4885POLB 3087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.